A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Phase 3

Active, not recruiting

• Conditions: Mucopolysaccharidosis II
• Interventions: Drug: Idursulfase; Drug: JR-141 or Idursulfase; Drug: JR-141

• Registration Number: NCT04573023
• Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Brief Summary

A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-17
• Study First Submitted QC: 2020-09-25
• Study First Posted: 2020-10-05
• Study Start: 2022-02-14
• Status Verified: 2025-10
• Last Update Submitted: 2025-10-02
• Last Update Posted: 2025-10-07
• Primary Completion: 2027-10-31
• Study Completion: 2027-10-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

• A patient who voluntarily signs an Institutional Review Board or Independent Ethics Committee-approved written informed consent form. If the patient is aged under 18 years (aged under 16 years in the UK) at the time of enrollment or willingness to participate in the study cannot be confirmed due to MPS II-related intellectual disability, the patient's legally acceptable representative (e.g., his/her parents or guardians) may sign the informed consent on behalf of the patient. Written informed assent should be obtained from the patient, wherever possible.
• Patients with confirmed diagnosis of MPS II
• Naïve patients or patients who are receiving stable enzyme replacement therapy with idursulfase for more than 12 weeks before starting administration of JR-141 or idursulfase for this study.
• Patients or patients whose partners are of child-bearing potential agree to use a medically accepted, highly effective method of contraception being use of condoms from the time of informed consent.

<Cohort A>

• Patients aged 36-42 months old at the time of ICF signing: patients must have a standard score measured by the BSID-III of 85 or less at screening.
• Patients aged 43-71 months old at the time of ICF signing: patients must EITHER have (1) A DQ measured by BSID-III of 20 to 85 at screening OR (2) A composite standard score on NVI measured by KABC-II of 85 or less at screening (only who can perform KABC-II)
• Patients aged 30-35 months old at the time of randomization and who are judged as having the severe phenotype by the Expert Board.

<Cohort B>

• Patients 6 years of age or older at the time of ICF signing and whose IQ are 70 and higher.
• Enrollment of subjects in Cohort B is contingent on the availability in that country of a validated country-specific version of the test (either WISC-V, WAIS-IV, or T.O.V.A.).
• Attenuated patients with 1 SD deficiency in the omission errors or variability domains of the T.O.V.A..
• Patients or patients whose female partners are of child-bearing potential i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile, agree to use a medically accepted, highly effective method of contraception, from the time of informed consent. The method of contraception must be used during the study until 90 days for male subjects, and 30 days for female subjects after the final study intervention administration.
• For subjects with hearing impairment requiring hearing aid(s), every effort has been made to encourage compliance with the use of functioning hearing aid(s) before baseline neurocognitive assessments, and parent/legally acceptable representative or subject agrees to encourage wearing them during the study and on neurocognitive testing days.

Exclusion Criteria

• A patient with a history of HSCT with successful engraftment.
• A patient who has received gene therapy treatment at any point.
• A patient who is judged by the principal investigator or sub-investigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely to experience breathing difficulties during the lumbar puncture process.
• A patient who is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device) within 4 months before obtaining informed consent.
• Unable to comply with the protocol as determined by the principal investigator or subinvestigator.
• Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity including anesthesia or hypersensitivity to any component of JR-141.
• A patient who has a known or suspected local or general infection or is at risk of abnormal bleeding due to medical conditions or therapies.
• A patient who has documented mutation of other genes, including loci adjacent to the IDS gene that are known to be associated with developmental delay, seizures, or other significant CNS disorders.
• A patient who has documented loss of activity of sulfatases other than IDS.
• A patient who has had a ventriculoperitoneal shunt placed or any other brain surgery, or has a clinically significant ventriculoperitoneal shunt malfunction within 30 days of screening.
• A patient who is full time employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members.
• A patient who otherwise is judged by the principle investigator or sub-investigator to be ineligible to participate in the study.
• The subject has a positive pregnancy test or is breastfeeding at screening or randomization.

[Only in France]

• Persons deprived of their liberty by a judicial or administrative decision, according to article L.1121-6 the Public Health Code (Code de la santé publique), adults who are the subject of a measure of legal protection or unable to express their consent according to article L. 1121-8 of the Code de la santé publique)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
administered as the standard of care: idursulfase (ELAPRASE®)	Idursulfase	standard of care-controlled study
Rescue arm	JR-141 or Idursulfase	-
JR-141 2.0 mg/kg/week	JR-141	-

Primary Outcome Measures

Name	Time	Method
Change in levels of cerebrospinal fluid heparan sulfate from baseline (Cohort A)	Baseline to Week 53
Change in the raw scores of cognitive testing measured from baseline (BSID-III) (Cohort A)	Baseline to Week 105

Secondary Outcome Measures

Name	Time	Method
For regions other than US: Change in the age equivalent scores of cognitive testing measured from baseline (BSID-III or KABC-II) (Cohort A)	Baseline to Week 105
For regions other than US: Change in the age equivalent scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)	Baseline to Week 105
For the US: Change in the raw scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)	Baseline to Week 105
For all regions: Relative change in liver volume relative to body weight from baseline (Cohort A and Cohort B)	Baseline to Week 53
For all regions: Relative change in spleen volume relative to body weight from baseline (Cohort A and Cohort B)	Baseline to Week 53

Trial Locations

Locations (29)

Phoenix Children's Hospital; 🇺🇸 Phoenix, Arizona, United States

UCSF Benioff Children's Hospital Oakland; 🇺🇸 Oakland, California, United States

Ann & Robert H. Lurie Children's Hospital of Chicago; 🇺🇸 Chicago, Illinois, United States

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States

Columbia University; 🇺🇸 New York, New York, United States

University of North Carolina at Chapel Hill Medical School Wing E; 🇺🇸 Chapel Hill, North Carolina, United States

Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States

Hospital Universitario Austral; 🇦🇷 Buenos Aires, Argentina

Hospital de Clínicas de Porto Alegre; 🇧🇷 Porto Alegre, Brazil

Instituto de Medicina Integral Prof. Fernando Figueira - Imip; 🇧🇷 Recife, Brazil

Scroll for more (19 remaining)